半剂量替格瑞洛对急性冠脉综合征患者经皮冠状动脉介入治疗术后的评价研究  

Evaluation study of half dose ticagrelor in the treatment of acute coronary syndrome patients after percutaneous coronary intervention

作　　者：范苗 姚佳琪 FAN Miao;YAO Jiaqi(Pharmaceutical Department,the First Affiliated Hospital of Ningbo University,Ningbo 315010,Zhejiang,China;Pharmaceutical Department,Ningbo NO.2 Hospital,Ningbo 315010,Zhejiang,China)

机构地区：[1]宁波大学附属第一医院药学部,浙江宁波315010 [2]宁波市第二医院药学部,浙江宁波315010

出　　处：《中国现代医生》2024年第31期76-80,89,共6页China Modern Doctor

摘　　要：目的探讨半剂量替格瑞洛在急性冠脉综合征(acute coronary syndrome,ACS)患者经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)术后的临床疗效及安全性。方法选取2017年1月至2019年11月于宁波大学附属第一医院成功接受PCI的108例ACS患者,根据替格瑞洛的使用剂量,将其分为标准剂量组(56例)和半剂量组(52例)。比较两组患者的主要不良心脑血管事件(major adverse cardiovascular and cerebrovascular event,MACCE)和安全性终点。结果两组患者的MACCE发生率比较差异无统计学意义(P>0.05)。半剂量组患者的安全性终点累积发生率显著低于标准剂量组(9.6%vs.28.6%,P<0.05)。两组患者的出血学术研究联合会(BleedingAcademicResearchConsortium,BARC)2/3型出血发生率比较差异无统计学意义(P>0.05),但半剂量组患者的BARC 1型出血发生率显著低于标准剂量组(P<0.05)。结论与标准剂量相比,半剂量替格瑞洛可降低出血风险,且不会增加患者的MACCE发生率。Objective To investigate clinical efficacy and safety of half dose ticagrelor in patients with acute coronary syndrome(ACS)undergoing percutaneous coronary intervention(PCI).Methods A total of 108 patients with ACS who successfully underwent PCI in the First Affiliated Hospital of Ningbo University from January 2017 to November 2019 were selected.According to the dosage of ticagrelor,the patients were divided into standard dose group(56 cases)and half dose group(52 cases).Major adverse cardiovascular and cerebrovascular event(MACCE)and safety endpoints were compared between two groups.Results There was no significant difference in the incidence of MACCE between two groups(P>0.05).The cumulative incidence of safety endpoints in half dose group was significantly lower than that in standard dose group(9.6%vs.28.6%,P<0.05).There was no significant difference in incidence of Bleeding Academic Research Consortium(BARC)type 2/3 bleeding between two groups(P>0.05).However,incidence of BARC type 1 bleeding in half dose group was significantly lower than that in standard dose group(P<0.05).Conclusion Compared with standard dose,half dose of ticagrelor can reduce the risk of bleeding and does not increase the incidence of MACCE in patients.

关 键 词：急性冠脉综合征 替格瑞洛 出血并发症 不良事件 

分 类 号：R541.4[医药卫生—心血管疾病]